Simeprevir and Sofosbuvir Combination Treatment in a Patient with HCV Cirrhosis and HbS Beta 0-Thalassemia: Efficacy and Safety despite Baseline Hyperbilirubinemia
Hyperbilirubinemia is an adverse reaction of simeprevir (SMV). The majority of these patients were taking concurrent ribavirin presenting elevated unconjugated hyperbilirubinemia due to hemolysis. However, cases of hepatic failure with elevated bilirubin level have also been reported in patients wit...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | Case Reports in Hematology |
| Online Access: | http://dx.doi.org/10.1155/2016/7635128 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832560526478016512 |
|---|---|
| author | Nikolaos Papadopoulos Melanie Deutsch Athanasios Georgalas Helias Poulakidas Lazaros Karnesis |
| author_facet | Nikolaos Papadopoulos Melanie Deutsch Athanasios Georgalas Helias Poulakidas Lazaros Karnesis |
| author_sort | Nikolaos Papadopoulos |
| collection | DOAJ |
| description | Hyperbilirubinemia is an adverse reaction of simeprevir (SMV). The majority of these patients were taking concurrent ribavirin presenting elevated unconjugated hyperbilirubinemia due to hemolysis. However, cases of hepatic failure with elevated bilirubin level have also been reported in patients with decompensated cirrhosis. We describe a 51-year-old female patient with HbS beta 0-thalassemia and recently diagnosed compensated cirrhosis due to chronic hepatitis C infection. Laboratory evaluation revealed total bilirubin: 2.7 mg/dL and serum HCV-RNA 137.204 IU/mL. HCV was genotyped as 4. A FibroScan revealed 35.3 kPa. She was considered as illegible for pegylated-interferon-free treatment with direct acting antivirals and a course with simeprevir and sofosbuvir (SOF) combination for twelve weeks was planned. Hyperbilirubinemia developed from the beginning with peak values during the 3rd month of treatment. However, no findings of liver decompensation were noticed. Hyperbilirubinemia was benign and fully reversible and our patient finally achieved sustained virological response 24 weeks after the end of treatment. |
| format | Article |
| id | doaj-art-6efbaa8331614a1d8e5cd5589e7cbae5 |
| institution | Kabale University |
| issn | 2090-6560 2090-6579 |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Hematology |
| spelling | doaj-art-6efbaa8331614a1d8e5cd5589e7cbae52025-02-03T01:27:16ZengWileyCase Reports in Hematology2090-65602090-65792016-01-01201610.1155/2016/76351287635128Simeprevir and Sofosbuvir Combination Treatment in a Patient with HCV Cirrhosis and HbS Beta 0-Thalassemia: Efficacy and Safety despite Baseline HyperbilirubinemiaNikolaos Papadopoulos0Melanie Deutsch1Athanasios Georgalas2Helias Poulakidas3Lazaros Karnesis4First Department of Internal Medicine, 401 General Army Hospital of Athens, 11525 Athens, GreeceSecond Department of Internal Medicine, Athens University Medical School, Hippokration Hospital of Athens, 11527 Athens, GreeceFirst Department of Internal Medicine, 401 General Army Hospital of Athens, 11525 Athens, GreeceHematology Department, 401 General Army Hospital of Athens, 11525 Athens, GreeceFirst Department of Internal Medicine, 401 General Army Hospital of Athens, 11525 Athens, GreeceHyperbilirubinemia is an adverse reaction of simeprevir (SMV). The majority of these patients were taking concurrent ribavirin presenting elevated unconjugated hyperbilirubinemia due to hemolysis. However, cases of hepatic failure with elevated bilirubin level have also been reported in patients with decompensated cirrhosis. We describe a 51-year-old female patient with HbS beta 0-thalassemia and recently diagnosed compensated cirrhosis due to chronic hepatitis C infection. Laboratory evaluation revealed total bilirubin: 2.7 mg/dL and serum HCV-RNA 137.204 IU/mL. HCV was genotyped as 4. A FibroScan revealed 35.3 kPa. She was considered as illegible for pegylated-interferon-free treatment with direct acting antivirals and a course with simeprevir and sofosbuvir (SOF) combination for twelve weeks was planned. Hyperbilirubinemia developed from the beginning with peak values during the 3rd month of treatment. However, no findings of liver decompensation were noticed. Hyperbilirubinemia was benign and fully reversible and our patient finally achieved sustained virological response 24 weeks after the end of treatment.http://dx.doi.org/10.1155/2016/7635128 |
| spellingShingle | Nikolaos Papadopoulos Melanie Deutsch Athanasios Georgalas Helias Poulakidas Lazaros Karnesis Simeprevir and Sofosbuvir Combination Treatment in a Patient with HCV Cirrhosis and HbS Beta 0-Thalassemia: Efficacy and Safety despite Baseline Hyperbilirubinemia Case Reports in Hematology |
| title | Simeprevir and Sofosbuvir Combination Treatment in a Patient with HCV Cirrhosis and HbS Beta 0-Thalassemia: Efficacy and Safety despite Baseline Hyperbilirubinemia |
| title_full | Simeprevir and Sofosbuvir Combination Treatment in a Patient with HCV Cirrhosis and HbS Beta 0-Thalassemia: Efficacy and Safety despite Baseline Hyperbilirubinemia |
| title_fullStr | Simeprevir and Sofosbuvir Combination Treatment in a Patient with HCV Cirrhosis and HbS Beta 0-Thalassemia: Efficacy and Safety despite Baseline Hyperbilirubinemia |
| title_full_unstemmed | Simeprevir and Sofosbuvir Combination Treatment in a Patient with HCV Cirrhosis and HbS Beta 0-Thalassemia: Efficacy and Safety despite Baseline Hyperbilirubinemia |
| title_short | Simeprevir and Sofosbuvir Combination Treatment in a Patient with HCV Cirrhosis and HbS Beta 0-Thalassemia: Efficacy and Safety despite Baseline Hyperbilirubinemia |
| title_sort | simeprevir and sofosbuvir combination treatment in a patient with hcv cirrhosis and hbs beta 0 thalassemia efficacy and safety despite baseline hyperbilirubinemia |
| url | http://dx.doi.org/10.1155/2016/7635128 |
| work_keys_str_mv | AT nikolaospapadopoulos simeprevirandsofosbuvircombinationtreatmentinapatientwithhcvcirrhosisandhbsbeta0thalassemiaefficacyandsafetydespitebaselinehyperbilirubinemia AT melaniedeutsch simeprevirandsofosbuvircombinationtreatmentinapatientwithhcvcirrhosisandhbsbeta0thalassemiaefficacyandsafetydespitebaselinehyperbilirubinemia AT athanasiosgeorgalas simeprevirandsofosbuvircombinationtreatmentinapatientwithhcvcirrhosisandhbsbeta0thalassemiaefficacyandsafetydespitebaselinehyperbilirubinemia AT heliaspoulakidas simeprevirandsofosbuvircombinationtreatmentinapatientwithhcvcirrhosisandhbsbeta0thalassemiaefficacyandsafetydespitebaselinehyperbilirubinemia AT lazaroskarnesis simeprevirandsofosbuvircombinationtreatmentinapatientwithhcvcirrhosisandhbsbeta0thalassemiaefficacyandsafetydespitebaselinehyperbilirubinemia |